Internal Medicine

Tuberculosis

The Ancient Scourge

Amos Asamoah
October 2025
6 min read
Other Topics

We're continuing our exploration of respiratory diseases with tuberculosis (TB) - one of humanity's oldest and most persistent infectious diseases. Despite modern medicine, TB remains a major global health challenge, particularly in developing countries. I'll guide you through the complex lifecycle of Mycobacterium tuberculosis, the spectrum of disease from latent infection to active TB, diagnostic challenges, and the intricate treatment regimens required. Understanding TB is crucial as it requires a unique approach combining public health measures with individual patient care. Let's unravel the mysteries of this formidable pathogen!

🩺 Overview and Epidemiology

Tuberculosis is caused by Mycobacterium tuberculosis complex, primarily affecting the lungs but capable of disseminating to virtually any organ. The global burden remains staggering despite available treatments.

Key Epidemiological Facts

  • ~10 million new cases annually worldwide
  • ~1.5 million TB-related deaths each year
  • One-third of world population has latent TB
  • Leading cause of death from infectious disease
  • HIV co-infection dramatically increases risk

High-Risk Populations

  • HIV-positive individuals
  • Healthcare workers
  • Immigrants from high-burden countries
  • Homeless and incarcerated persons
  • Elderly and immunocompromised
Transmission Factor Impact Prevention Strategy
Airborne droplets Primary route of spread Respiratory isolation, ventilation
Infectious dose Low inoculum can cause infection Early detection and treatment
Duration of exposure Prolonged contact increases risk Limit exposure to active cases
Host immunity Determines progression to active disease Address risk factors, BCG vaccination
Clinical Pearl: Remember that only pulmonary TB is contagious. Extrapulmonary TB (except laryngeal) does not transmit through casual contact.

🔄 Pathophysiology and Disease Spectrum

TB infection follows a complex pathway from initial exposure through various clinical states, determined by the balance between bacterial virulence and host immunity.

Primary Infection

  • Inhalation of droplet nuclei
  • Alveolar macrophage ingestion
  • Ghon focus formation
  • Lymphatic spread to hilar nodes
  • Ghon complex (focus + nodes)

Latent TB Infection

  • Contained by immune system
  • No symptoms, not contagious
  • Positive TB test results
  • Risk of reactivation (5-10% lifetime)
  • Higher risk if immunocompromised

Active TB Disease

  • Primary progressive or reactivation
  • Clinical symptoms present
  • Contagious (if pulmonary)
  • Tissue destruction and cavitation
  • Can disseminate (miliary TB)
Tutor Tip: Think of TB infection as a spectrum: Exposure → Primary Infection → Latent TB → Active TB. The immune system determines where along this spectrum an individual remains.

👨‍⚕️ Clinical Presentation

TB symptoms vary based on disease site, immune status, and whether it's primary or reactivation disease. Pulmonary TB is most common, but extrapulmonary manifestations are frequent in immunocompromised hosts.

Pulmonary TB Symptoms

Constitutional Symptoms

  • Fever, night sweats
  • Weight loss, anorexia
  • Fatigue, malaise
  • Evening temperature elevation

Respiratory Symptoms

  • Chronic cough (>3 weeks)
  • Hemoptysis (late symptom)
  • Chest pain, dyspnea
  • Sputum production

Extrapulmonary TB Presentations

Site Frequency Key Features Diagnostic Clues
Lymphatic Most common extrapulmonary Painless lymphadenopathy Cervical nodes, cold abscesses
Pleural Second most common Pleuritic pain, effusion Exudative lymphocytic effusion
Genitourinary Common in young adults Sterile pyuria, flank pain Urine cultures, renal calcifications
Bone/Joint Pott's disease (spine) Back pain, deformity Gibbus deformity, paravertebral abscess
Miliary Disseminated disease Non-specific, multi-organ Millet seed appearance on CXR
Meningeal Most severe form Headache, meningismus Basilar meningitis on imaging
TB Emergency: Meningitis, pericarditis with tamponade, massive hemoptysis, or respiratory failure from extensive pulmonary disease require immediate hospitalization and specialized care.

🔍 Diagnostic Approach

TB diagnosis requires a high index of suspicion and utilizes multiple modalities including imaging, microbiological tests, and immunological assays.

Diagnostic Methods

Test Purpose Advantages Limitations
Chest X-ray Initial screening Widely available, quick Non-specific, cannot confirm diagnosis
Sputum Smear Detect acid-fast bacilli Rapid, identifies contagious cases Low sensitivity (requires 5000-10000 bacilli/mL)
Culture Gold standard diagnosis High sensitivity, drug susceptibility Slow (2-8 weeks), specialized labs
NAAT (Xpert MTB/RIF) Rapid molecular diagnosis Results in 2 hours, detects rifampin resistance Cost, equipment requirements
TST (Mantoux) Detect infection (latent/active) Inexpensive, widely available False positives (BCG, NTM), false negatives (anergy)
IGRA (Quantiferon/T-Spot) Detect infection More specific, not affected by BCG Cost, cannot distinguish latent/active
Important: Always obtain at least 3 sputum samples (including one early morning) for AFB smear and culture when pulmonary TB is suspected. Never rule out TB based on a single negative test.

💊 Treatment Strategies

TB treatment requires multiple drugs for extended periods to prevent resistance and ensure cure. Regimens differ for drug-susceptible vs drug-resistant TB.

Drug-Susceptible TB Treatment

Phase Duration Regimen Key Drugs Monitoring
Intensive Phase 2 months RIPE regimen Rifampin, Isoniazid, Pyrazinamide, Ethambutol Weekly then monthly LFTs, visual acuity
Continuation Phase 4 months RI regimen Rifampin, Isoniazid Monthly clinical assessment, sputum conversion
Extended Phase 7-12 months additional Based on site CNS, bone: 9-12 months total Individualized monitoring

First-Line Anti-TB Drugs

Key Drugs and Monitoring

  • Isoniazid: Hepatotoxicity, peripheral neuropathy
  • Rifampin: Orange bodily fluids, drug interactions
  • Pyrazinamide: Hyperuricemia, hepatotoxicity
  • Ethambutol: Optic neuritis (color vision first)
  • Streptomycin: Ototoxicity, nephrotoxicity

Special Considerations

  • Directly Observed Therapy (DOT)
  • Pyridoxine (B6) with INH
  • Pregnancy: Avoid streptomycin
  • HIV co-infection: Adjust duration
  • Liver disease: Modified regimens
Treatment Principle: "Never add a single drug to a failing regimen" - this prevents sequential acquisition of resistance and development of MDR-TB.

⚠️ Drug-Resistant TB

Drug-resistant TB, particularly MDR-TB (multidrug-resistant) and XDR-TB (extensively drug-resistant), poses significant treatment challenges and public health threats.

Definitions

  • MDR-TB: Resistant to INH and Rifampin
  • Pre-XDR TB: MDR-TB + resistant to fluoroquinolone
  • XDR-TB: MDR-TB + resistant to fluoroquinolone and at least one second-line injectable
  • RR-TB: Rifampin-resistant (treated as MDR)

Treatment Approach

  • Specialized regimens (18-24 months)
  • Second-line drugs: Fluoroquinolones, injectables
  • Newer drugs: Bedaquiline, Delamanid
  • Individualized based on DST results
  • Always under expert supervision
Clinical Insight: Suspect drug-resistant TB in treatment failures, relapses, contacts of known MDR-TB cases, and immigrants from high MDR-TB burden countries.

🌱 Prevention and Public Health

TB control requires integrated approaches including case finding, treatment completion, infection control, and preventive therapy.

Latent TB Treatment

  • Isoniazid for 9 months
  • Rifampin for 4 months
  • 3-month INH-Rifapentine (weekly)
  • Target high-risk individuals
  • Prevents reactivation

Infection Control

  • Respiratory isolation for active cases
  • Negative pressure rooms
  • N95 respirators for healthcare workers
  • UV germicidal irradiation
  • Ventilation improvements

Public Health Measures

  • Contact investigation
  • Directly Observed Therapy
  • BCG vaccination in high-burden areas
  • Global TB control programs
  • Drug resistance surveillance
Pro Tip: Always report TB cases to public health authorities - this is legally required and essential for contact tracing and outbreak control.

🧠 Key Takeaways

  • TB remains a major global health problem with high morbidity and mortality
  • Infection spectrum ranges from latent (asymptomatic) to active (contagious) disease
  • Pulmonary TB is most common, but extrapulmonary forms affect many organs
  • Diagnosis requires multiple methods: imaging, microscopy, culture, molecular tests
  • Standard treatment is 6 months with 4 drugs initially, then 2 drugs
  • Drug resistance (MDR/XDR-TB) requires prolonged, complex regimens
  • Directly Observed Therapy improves adherence and outcomes
  • Public health measures are crucial for TB control and prevention

🧭 Conclusion

We've explored the complex world of tuberculosis, student—from its intricate pathophysiology to the challenges of diagnosis and the critical importance of complete treatment. Remember that TB requires a comprehensive approach combining individual patient care with public health measures. I encourage you to maintain a high index of suspicion for TB, especially in high-risk populations, and to understand the principles of TB control. Excellent work mastering this challenging topic! Next, we'll examine lung cancer and its various presentations and management strategies.

In tuberculosis management, completing the full course of treatment is as important as starting it - defaulters risk treatment failure and drug resistance.

← Previous Topic: Pneumonia Next Topic: Lung Cancer →